The development of new drugs is an expensive process that requires extensive testing of a drug's mechanism of action and safety. Although many compounds are designed for the ability to exert a desired biological effect, few perform satisfactorily as drugs due to unexpected modes of action in vivo. The investigators have developed a battery of retrovirus-based technologies that allow for the isolation of genes based on their function in tissue culture cells. The investigators state that in the Phase I proposal they have taken advantage of the inhibition of cellular proliferation by anti-hypertensive calcium channel blockers to isolate gene products that are important to the action of these drugs. They also state that preliminary studies have demonstrated the feasibility of employing this approach on a large scale to identify gene products involved in calcium physiology and cell proliferation control. In this application they propose to carry out exhaustive screens for genes that confer resistance to dihydropyridine calcium channel blockers from diverse tissue types, to categorize these gene products with respect to mechanism of drug resistance, and to identify relevant drug targets among them.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44GM059496-02
Application #
6144543
Study Section
Special Emphasis Panel (ZRG1-SSS-Y (01))
Program Officer
Okita, Richard T
Project Start
1999-05-01
Project End
2003-04-30
Budget Start
2001-05-01
Budget End
2002-04-30
Support Year
2
Fiscal Year
2001
Total Cost
$413,696
Indirect Cost
Name
Genetica, Inc.
Department
Type
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02139